Also, the model's predictions demonstrate that SGLT2 inhibition decreases the chronic rate of decline in GFR and reduce onset of albuminuria in normoglycemic CKD through improvements in glomerular HTN via TGF. The gene discussed is SLC5A2; the disease is chronic kidney disease.